11 | February | 2025 | Living Well Study

In a recent publication in the Journal of Affective Disorders, scientists Pearl Chiu and Brooks Casas from the Fralin Biomedical Research Institute at Virginia Tech have embarked on a study investigating how the brain’s mechanisms for reward learning could revolutionize the treatment of depression. The study focuses on a particular brain signal that activates in anticipation of rewards, which could be key to developing methods to help individuals overcome depression. Professors Chiu and Casas are at the forefront of this innovative approach, aiming to tailor depression therapies by examining how individuals process rewards and setbacks.

Their research, unveiled in January, delves into two specific brain signals: prediction error and expected value. These signals might enable predictions about the improvement of depressive symptoms in patients. This groundbreaking work is rooted in the understanding that significant depression, affecting over 21 million Americans annually, according to the Centers for Disease Control and Prevention, requires more than a one-size-fits-all treatment approach due to its complexity and the diverse ways it manifests in different individuals.

Professor Chiu explains that depression varies widely among individuals, particularly in how they learn from and respond to positive and negative events, often correlating with specific depressive symptoms. The team employs computational models to analyze how the reward-learning system of the brain operates in depressed individuals, particularly those experiencing anhedonia—a condition characterized by a diminished ability to experience pleasure. Their findings, which link specific brain activity patterns to potential recovery outcomes, suggest that these unique patterns could be pivotal in predicting who might recover from depression.

Chiu emphasizes that understanding the brain’s capacity to learn from various outcomes could lead to novel therapeutic approaches that utilize customized learning processes to adjust the brain’s reactions to these outcomes. The study identifies the brain signals of prediction error and expected value as crucial markers for determining the potential for recovery from depression. The expected value signal, indicative of the brain’s reward anticipation, consistently predicts remission across different treatment modalities. In contrast, the prediction error signal provides additional insights by highlighting the discrepancy between expected and actual outcomes, helping individuals adjust their behaviours accordingly.

This dual-signal approach enriches understanding of how distinct learning patterns can influence mental health outcomes, potentially leading to personalized, symptom-specific therapies. According to Professor Casas, these findings highlight the significant role of the brain’s reward system in predicting recovery, enabling the development of treatment plans that are aligned with each individual’s unique response patterns to rewards and setbacks.

Vansh Bansal, the study’s first author and a graduate student working with Chiu and Casas, notes that this research marks a significant step towards genuinely personalized mental health care. The team is actively applying these insights, having published related research in Clinical Psychological Science earlier in the year, which explored how reinforcement-learning techniques could influence behavioural changes in depressed individuals. They are now testing specific reinforcement-related questions that could alter how people with depression react to rewards and setbacks.

The overarching aim of this research is to move beyond mere symptom management by targeting the underlying brain processes that drive specific depressive symptoms. This approach promises more targeted interventions that offer lasting benefits by aligning therapeutic strategies with each individual’s unique brain responses. This innovative research signifies a significant advancement in integrating brain science with therapeutic practices, paving the way for more effective, personalized treatment methods. By comprehending how the brain’s reward system operates, the researchers are crafting strategies that could fundamentally transform care for depression by tackling its root causes rather than merely addressing its symptoms.

More information: Vansh Bansal et al, Reinforcement learning processes as forecasters of depression remission, Journal of Affective Disorders. DOI: 10.1016/j.jad.2024.09.066

Journal information: Journal of Affective Disorders Provided by Virginia Tech

Cystic fibrosis is a disease caused by inherited genetic mutations that disrupt or entirely stop the production of the CFTR protein. This condition primarily impacts the respiratory system, where mucus becomes so thick that it prevents pathogens like bacteria from being expelled through coughing, leading to a dangerous cycle of infection and inflammation.

To mitigate these effects, medical professionals have increasingly turned to CFTR modulator therapies in recent years. These treatments enhance the protein’s function, reducing mucus production and significantly improving the quality of life for those affected. Despite these advancements, clinical studies indicate that airway inflammation is still common, and in older patients, the deterioration of lung function continues unabated.

Ongoing research is dedicated to uncovering further processes involved in cystic fibrosis. Professor Nikolai Klymiuk from the Technical University of Munich, part of an international research team, has focused on how the immune system behaves in cystic fibrosis before the cycle of infection and inflammation begins. Their findings, published in Science Translational Medicine, reveal significant insights into the immune response associated with the disease.

The research team found that specific innate immune system cells in blood samples from children with cystic fibrosis and pigs with the same genetic defect are immature. This immaturity makes them less effective at fighting off bacteria. Additionally, pigs with cystic fibrosis also showed an increased number and significantly altered composition of immune cells in their lungs from birth. Given the strong resemblance between the immune systems of pigs and humans, these observations are likely applicable to human patients as well.

The researchers propose that these changes in the immune system may result from an “emergency program,” which prompts the body to produce many immune cells quickly and over a prolonged period. This leads to the formation of immature immune cells, which contribute to the fatal cycle of infections and inflammation characteristic of cystic fibrosis. Although these cells are present in the lungs, they are ineffective and damage lung tissue without preventing infections over the long term.

Professor Klymiuk, who specializes in Cardiovascular Translation in Large Animal Models at TUM, notes that while it remains unclear why such changes in immune cells occur, they are evident early in life and persist throughout the individual’s lifetime. Previously thought to result from frequent infections in adults, these altered immune cells are now understood to be a fundamental aspect of the disease from its onset. Professor Klymiuk believes that to enable people with cystic fibrosis to live without symptoms, a comprehensive approach to treating the disease is necessary. He hopes that the insights from their research will lead to a better understanding of the defective immune system and inform future treatment strategies.

More information: Nikolai Klymiuk et al, Perinatal dysfunction of innate immunity in cystic fibrosis, Science Translational Medicine. DOI: 10.1126/scitranslmed.adk9145

Journal information: Science Translational Medicine Provided by Technical University of Munich (TUM)

Living Well Study

Daily Archives: 11 February 2025

Understanding How the Brain Learns from Rewards Could Unlock New Treatments for Depression

Cystic Fibrosis Impairs the Immune System at an Early Stage